Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.
about
Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Efficacy and safety of third-l ...... bitor and second-line therapy.
@en
Efficacy and safety of third-l ...... bitor and second-line therapy.
@nl
type
label
Efficacy and safety of third-l ...... bitor and second-line therapy.
@en
Efficacy and safety of third-l ...... bitor and second-line therapy.
@nl
prefLabel
Efficacy and safety of third-l ...... bitor and second-line therapy.
@en
Efficacy and safety of third-l ...... bitor and second-line therapy.
@nl
P2093
P2860
P50
P1476
Efficacy and safety of third-l ...... ibitor and second-line therapy
@en
P2093
Hidekazu Tachibana
Hirohito Kobayashi
Junpei Iizuka
Kazunari Tanabe
Toshio Takagi
Tsunenori Kondo
P2860
P2888
P304
P356
10.1007/S10147-018-1241-3
P577
2018-01-11T00:00:00Z